Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding
Key result
Improved adherence to antithrombotic guidelines could have potentially prevented 22% to 25% of ischemic strokes in patients with atrial fibrillation.
Population
Patients with atrial fibrillation
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
This editorial emphasizes the importance of adherence to antithrombotic guidelines in atrial fibrillation and advocates for the use of simplified risk stratification tools like CHA2DS2-VASc and HAS-BLED.
Key Points
- Assess causes of guideline non-adherence for antithrombotic therapy in atrial fibrillation and discuss simplified stratification tools for stroke and bleeding risks.
- Narrative clinical review evaluating data on guideline adherence, stroke incidence, and bleeding complications in patients with atrial fibrillation.
- Analysis of risk stratification frameworks including the CHADS2, CHA2DS2-VASc, and HAS-BLED schemas.
- Real-world evidence indicates 51% of eligible patients with atrial fibrillation did not receive vitamin K antagonists, and strict guideline adherence could have prevented 22% to 25% of ischemic strokes.
- Adjusted-dose vitamin K antagonists reduce stroke incidence by ~65% compared with placebo, whereas antiplatelet agents achieve a ~20% reduction while presenting comparable major bleeding risks.
- The HAS-BLED bleeding risk score demonstrated a c-statistic of 0.72 for major bleeding in the overall cohort, rising to 0.85 in untreated cohorts and 0.91 in patients receiving antiplatelet therapy alone.
Structured PICO
P
Population
Patients with atrial fibrillation
I
Intervention
Antithrombotic therapy (vitamin K antagonists or antiplatelet agents)
This editorial emphasizes the importance of adherence to antithrombotic guidelines in atrial fibrillation and advocates for the use of simplified risk stratification tools like CHA2DS2-VASc and HAS-BLED.
Limitations
- The evaluation of benefit was based on medical literature rather than a direct comparison of two medical managements, making the method somewhat speculative.
Cite This Study
Fauchier et al. (2010) conducted an editorial in Atrial fibrillation. Guideline-adherent antithrombotic therapy vs. Non-adherence to guidelines was evaluated on Ischemic stroke. Improved adherence to antithrombotic guidelines could have potentially prevented 22% to 25% of ischemic strokes in patients with atrial fibrillation.